Current and emerging therapies for corneal neovascularization

D Roshandel, M Eslani, A Baradaran-Rafii… - The ocular …, 2018 - Elsevier
The cornea is unique because of its complete avascularity. Corneal neovascularization
(CNV) can result from a variety of etiologies including contact lens wear; corneal infections; …

[HTML][HTML] Up-to-date molecular medicine strategies for management of ocular surface neovascularization

Y Yang, J Zhong, D Cui, LD Jensen - Advanced Drug Delivery Reviews, 2023 - Elsevier
Ocular surface neovascularization and its resulting pathological changes significantly alter
corneal refraction and obstruct light path to the retina, and hence is a major cause of vision …

Inhibiting corneal neovascularization by sustainably releasing anti-VEGF and anti-inflammation drugs from silica-thermogel nanohybrids

N Lyu, Y Zhao, J Xiang, X Fan, C Huang, X Sun… - Materials Science and …, 2021 - Elsevier
Corneal neovascularization (CNV) is one of the main factors that induce blindness
worldwide. To effectively inhibit CNV, a novel nanohybrid has been developed by …

Pharmacological potential of small molecules for treating corneal neovascularization

Z Barry, B Park, TW Corson - Molecules, 2020 - mdpi.com
Under healthy conditions, the cornea is an avascular structure which allows for transparency
and optimal visual acuity. Its avascular nature is maintained by a balance of proangiogenic …

Assessment of therapeutic options for reducing alkali burn-induced corneal neovascularization and inflammation

A Bakunowicz-Łazarczyk, B Urban - Advances in Medical Sciences, 2016 - Elsevier
This article aims to review and provide the current knowledge of the possibilities of topical
treatment of corneal neovascularization due to alkali burns, evidenced by laboratory …

Effects of dexamethasone on C6 cell proliferation, migration and invasion through the upregulation of AQP1

Y Guan, J Chen, Y Zhan, H Lu - Oncology letters, 2018 - spandidos-publications.com
Dexamethasone (Dex) is commonly used to treat glioma; however, the mechanism
underlying the action of Dex remains unclear. In the present study, the hypothesis that …

Recent drug therapies for corneal neovascularization

X Liu, S Wang, X Wang, J Liang… - Chemical Biology & …, 2017 - Wiley Online Library
Corneal neovascularization (CNV) is a common pathological change in ocular surface
diseases. It is not only the factor that affects vision but also the main cause for corneal graft …

[HTML][HTML] The clinical findings, follow-up and treatment results in patients with ocular rocasea

İ Kılıç Müftüoğlu, Y Aydın Akova - 2016 - jag.journalagent.com
Purpose: To report the clinical features, treatment options and complications in patients with
ocular rosacea. Patients and Material-Methods: The records of 48 eyes 24 patients with …

Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization

H Cakmak, E Gokmen, G Bozkurt… - Cutaneous and Ocular …, 2018 - Taylor & Francis
Aim: To evaluate the effects of sunitinib (0.5 mg/ml) and bevacizumab (5 mg/ml) on VEGF-A,
VEGFR-2 and microRNA (miRNA) levels on corneal neovascularization (CNV). Methods: In …

[HTML][HTML] Management of corneal neovascularization: Current and emerging therapeutic approaches

D Wu, KE Chan, BXH Lim, DKA Lim… - Indian Journal of …, 2024 - journals.lww.com
Corneal neovascularization (CoNV) is a sight-threatening condition affecting an estimated
1.4 million people per year, and the incidence is expected to rise. It is a complication of …